Member Info for Hurst10

Further M&A from the majors in the Oncology sector:
Roche snaps up PD-1-focused Good Therapeutics for $250M; 'Sky's the limit' for spinout.

ODD : The increase in approvals is leading industry experts to value the global orphan drug market at $300 billion by 2026, more than 20% of global prescription drug sales3, up from $132 billion in 2019.

40/+ buy prints going through again

Suspect we will have key MM back on the bid, approaching ESMO on Friday

Heading for est 300/ being picked up in the last 40min.
NY waking up and have the usual on the bids.
FDA news is something Conifer,Sequoia, Blackrock understands!!

Starts in Paris Friday:
ESMO 2022, the world's premier congress in medical oncology!All major Pharma’s will be there
The congress will attract an international community of experts, across disciplines and all focused on finding the most effective cancer treatment solutions available today.

Myles McNulty back tweeting buy case for very cheap Avacta.
100/ buy went through

FDA before ESMO
Novartis …

Yesterday I noticed an off market print post hours: timed 12.05
Bought 27,483 at 132.25

Ref Affyxell :
Full article can be provided.
“ Investigators at the University of Oregon (UO) have recently uncovered molecular events experienced by stem cells as they age, which could provide new avenues toward the discovery of novel therapies for cancer and neurological disorders. The researchers noticed that these changes arise in Drosophila during the development of the central nervous and at that time a specific protein is expressed, blocking tumor formation. “

The next 90 min will create a strong size buying interest, with 50/ buying units picking up stock.
With the interest there was around ASCO, Novartis, Takeda, Roche etc will all be at ESMO and we could have quite an interesting week.
With Novartis disposing of Sandoz, we could see companies like Novartis taking advantage of outsized cash holdings and pick up depressed valuations with unique assets like Avacta !

Last 20 min, the 50/ purchase crowd is back from last night and picking up stock at 120 and below, very clever pre Next week and ESMO and further news flow !

No wonder we are getting good size market buy orders print!

Worth remembering that US patients can commence at
Cohort 200mg dosage and share the data in the approval process.

With ESMO starting next week in Paris and all the majors attending, Point Biopharma presenting additional info, todays news from Avacta and more to come and the usual market makers on the bid in front of NY opening, all interesting!

Since 13.15
7x 10/ purchased

Something that Avacta would be discussing with the FDA:

Fast Track Designation is intended to facilitate development and expedite the review of drugs that treat serious conditions and fill an unmet medical need so a product can potentially be approved and reach patients more quickly. Fast Track Designation enables the company to have more frequent interactions with the FDA throughout the drug development process and allows for eligibility for priority review and accelerated approval if certain criteria are met, as well as a rolling review

Look who is back on the bid !

The happiest chap in town BEGO!
119bid 26 offered
Watch him during the afternoon reverse that and will buy anything below 35
Classic trick

Suspect once we have AVA6000 in phase 1 trial mode, it will receive a priority review status by the FDA.
The majors at ESMO should be keen to have a conservation with Avacta.
Point Biopharma is also doing another presentation at ESMO. Keeping the strong momentum going.